St. Johns Investment Management Company LLC Has $74,000 Position in GlaxoSmithKline plc (NYSE:GSK)

St. Johns Investment Management Company LLC reduced its stake in GlaxoSmithKline plc (NYSE:GSK) by 28.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,852 shares of the pharmaceutical company’s stock after selling 742 shares during the period. St. Johns Investment Management Company LLC’s holdings in GlaxoSmithKline were worth $74,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of GSK. Equity Investment Corp boosted its position in GlaxoSmithKline by 3.9% during the 1st quarter. Equity Investment Corp now owns 2,776,791 shares of the pharmaceutical company’s stock worth $116,042,000 after buying an additional 105,044 shares during the period. Parametric Portfolio Associates LLC boosted its position in GlaxoSmithKline by 4.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 2,765,250 shares of the pharmaceutical company’s stock worth $115,560,000 after buying an additional 107,713 shares during the period. Brandes Investment Partners LP boosted its position in GlaxoSmithKline by 2.1% during the 1st quarter. Brandes Investment Partners LP now owns 2,085,398 shares of the pharmaceutical company’s stock worth $87,149,000 after buying an additional 42,656 shares during the period. Dimensional Fund Advisors LP boosted its position in GlaxoSmithKline by 5.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock worth $67,626,000 after buying an additional 88,148 shares during the period. Finally, Kahn Brothers Group Inc. DE boosted its position in GlaxoSmithKline by 1.2% during the 1st quarter. Kahn Brothers Group Inc. DE now owns 1,276,550 shares of the pharmaceutical company’s stock worth $53,347,000 after buying an additional 15,610 shares during the period. Institutional investors own 11.25% of the company’s stock.

GlaxoSmithKline stock traded down $0.43 during mid-day trading on Friday, hitting $41.05. 2,319,963 shares of the stock were exchanged, compared to its average volume of 2,496,513. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $42.47. The firm’s fifty day moving average price is $40.83. The firm has a market capitalization of $101.83 billion, a PE ratio of 12.99, a price-to-earnings-growth ratio of 2.01 and a beta of 0.71.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The firm had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. On average, analysts forecast that GlaxoSmithKline plc will post 2.91 earnings per share for the current year.

In other news, Director Plc Glaxosmithkline purchased 333,333 shares of the stock in a transaction on Monday, July 1st. The stock was purchased at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.00% of the stock is currently owned by company insiders.

Several research firms recently commented on GSK. Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. Cowen reiterated a “hold” rating and set a $45.00 target price on shares of GlaxoSmithKline in a research report on Monday, June 10th. Finally, Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $42.66.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.